NZ604018A - Furanyl compounds and the use thereof - Google Patents

Furanyl compounds and the use thereof

Info

Publication number
NZ604018A
NZ604018A NZ604018A NZ60401811A NZ604018A NZ 604018 A NZ604018 A NZ 604018A NZ 604018 A NZ604018 A NZ 604018A NZ 60401811 A NZ60401811 A NZ 60401811A NZ 604018 A NZ604018 A NZ 604018A
Authority
NZ
New Zealand
Prior art keywords
compounds
amelioration
prevention
treatment
furanyl
Prior art date
Application number
NZ604018A
Other languages
English (en)
Inventor
Cathy A Swindlehurst
Leah M Fung
Kyle W H Chan
Original Assignee
Novomedix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomedix Llc filed Critical Novomedix Llc
Publication of NZ604018A publication Critical patent/NZ604018A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
NZ604018A 2010-06-07 2011-06-07 Furanyl compounds and the use thereof NZ604018A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35230810P 2010-06-07 2010-06-07
PCT/US2011/039377 WO2011156321A1 (en) 2010-06-07 2011-06-07 Furanyl compounds and the use thereof

Publications (1)

Publication Number Publication Date
NZ604018A true NZ604018A (en) 2015-02-27

Family

ID=44210539

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ604018A NZ604018A (en) 2010-06-07 2011-06-07 Furanyl compounds and the use thereof

Country Status (11)

Country Link
US (3) US8722731B2 (enExample)
EP (1) EP2576532B1 (enExample)
JP (1) JP5855095B2 (enExample)
CN (2) CN104860907A (enExample)
AU (1) AU2011265047B2 (enExample)
CA (1) CA2801778C (enExample)
MX (2) MX367469B (enExample)
NZ (1) NZ604018A (enExample)
SG (1) SG186229A1 (enExample)
WO (1) WO2011156321A1 (enExample)
ZA (1) ZA201209237B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367469B (es) 2010-06-07 2019-08-23 Novomedix Llc Compuestos furanilo y su uso.
EP3345596B1 (en) * 2012-09-21 2021-01-20 Rhode Island Hospital Inhibitors of beta-hydrolase for treatment of cancer
ES2689921T3 (es) * 2012-11-30 2018-11-16 Novomedix, Llc Biarilsulfonamidas sustituidas y sus usos
WO2015088977A1 (en) * 2013-12-10 2015-06-18 Emory University Targeted protease compositions and uses related thereto
CN106102775A (zh) 2014-02-07 2016-11-09 效应物治疗公司 治疗纤维变性疾病的方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
AU2021230289A1 (en) * 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
DE3933573A1 (de) 1989-10-07 1991-04-18 Basf Ag Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
CA2119155C (en) 1991-10-18 1999-06-15 Dennis Paul Phillion Fungicides for the control of take-all disease of plants
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
HRP921338B1 (en) 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
US5248221A (en) 1992-10-22 1993-09-28 Rohm And Haas Company Antifouling coating composition comprising lactone compounds, method for protecting aquatic structures, and articles protected against fouling organisms
US5334389A (en) 1992-10-15 1994-08-02 Duke University Antifouling coating and method for using same
US5259701A (en) 1992-10-22 1993-11-09 Rohm And Haas Company Antifouling coating composition comprising furan compounds, method for protecting aquatic structures, and articles protected against fouling organisms
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1266582B1 (it) 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
WO1995005739A1 (en) 1993-08-24 1995-03-02 Janssen Pharmaceutica N.V. Antibacterial and antifouling oxathiazines and their oxides
MX9406411A (es) 1993-08-24 1997-08-30 Uniroyal Chem Co Inc Oxatiazinas conservadoras de madera.
US5789419A (en) 1994-06-09 1998-08-04 Ss Pharmaceutical Co., Ltd. 4-quinolinone derivative or salt thereof
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
KR100353304B1 (ko) 1996-10-01 2002-09-30 에스알아이 인터내셔널 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DK0839525T3 (da) 1996-10-31 2004-11-29 Takeda Pharmaceutical Præparat med forlænget frigivelse
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
ES2196396T3 (es) 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
EP1072263A4 (en) 1998-03-26 2004-03-31 Japan Tobacco Inc AMID DERIVATIVES AND NOCICEPTINANT AGONISTS
EP0957099B1 (en) 1998-04-15 2002-11-20 Pfizer Products Inc. Heterocyclic carboxamides
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
AU761327B2 (en) 1998-08-04 2003-06-05 Toray Industries, Inc. Fused benzene heterocycle derivatives and utilization thereof
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE69926148D1 (en) 1998-11-09 2005-08-18 Black James Foundation Gastrin und cholecystokinin rezeptor ligande
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
KR20020016839A (ko) 1999-06-24 2002-03-06 무라타 도시카즈 복소환 디카르복실산 디아미드 유도체, 농원예용 살충제및 그것의 사용 방법
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
GB0018758D0 (en) 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
GB0117531D0 (en) 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003028641A2 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
TW200302726A (en) 2002-01-31 2003-08-16 Ono Pharmaceutical Co Nitrogen-containing bicyclic compound and medicament containing same as active ingredient
EP1501829B1 (en) 2002-05-06 2010-11-24 Vertex Pharmaceuticals Incorporated Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
DE60319714T2 (de) 2002-06-19 2009-04-02 Schering Corp. Agonisten des cannabinoidrezeptors
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
AU2003290700A1 (en) 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7262197B2 (en) 2003-03-31 2007-08-28 Janssen Pharmaceutica, N.V Phospholipase C inhibitors for use in treating inflammatory disorders
JP2004315511A (ja) 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
US20040248972A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20040248957A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
WO2004108133A2 (en) 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
US20050222408A1 (en) 2003-07-14 2005-10-06 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
AR045238A1 (es) 2003-08-08 2005-10-19 Vertex Pharma Compuestos utiles como inhibidores de canales ionicos regulados por voltaje
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
TW200519202A (en) * 2003-09-18 2005-06-16 Lilly Co Eli Modulation of eIF4E expression
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
CA2540828A1 (en) 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
JP2005314347A (ja) 2004-04-30 2005-11-10 Japan Tobacco Inc 疼痛抑制剤
US7470722B2 (en) * 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
NZ552173A (en) 2004-06-25 2010-07-30 Janssen Pharmaceutica Nv Quaternary salt CCR2 antagonists
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20150002863A (ko) 2004-09-02 2015-01-07 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
WO2006065946A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
WO2006120104A1 (en) 2005-04-11 2006-11-16 Probiodrug Ag Inhibitors of prolyl endopeptidase
WO2007016292A2 (en) 2005-07-27 2007-02-08 Vertex Pharmaceuticals Incorporated Heterocyclic amides as biofilm modulators
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
AU2006307314C1 (en) 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
EP1963313B1 (en) 2005-11-28 2012-11-14 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase (dgat)
BRPI0620464A2 (pt) 2005-12-23 2011-11-16 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体
CN101622244A (zh) * 2006-11-03 2010-01-06 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2008112913A1 (en) * 2007-03-14 2008-09-18 Exelixis, Inc. Inhibitors of the hedgehog pathway
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
ES2476605T3 (es) 2007-04-24 2014-07-15 Shionogi & Co., Ltd. Derivados de aminohidrotiazina sustituidos con grupos cíclicos
US20100137312A1 (en) * 2007-05-15 2010-06-03 Neurosearch A/S Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators
US20090099201A1 (en) 2007-05-22 2009-04-16 David Robert Bolin Diacylglycerol Acyltransferase Inhibitors
US8115011B2 (en) 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8153644B2 (en) 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
AU2008310660A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US8093428B2 (en) 2007-10-26 2012-01-10 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
US8168829B2 (en) 2007-10-26 2012-05-01 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
EP2210876B1 (en) 2007-11-01 2015-05-20 Takeda Pharmaceutical Company Limited Heterocyclic compound as glucagon antagonist
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
MX367469B (es) 2010-06-07 2019-08-23 Novomedix Llc Compuestos furanilo y su uso.

Also Published As

Publication number Publication date
MX2012014273A (es) 2013-03-22
US9663483B2 (en) 2017-05-30
AU2011265047A1 (en) 2013-01-10
CN103108868A (zh) 2013-05-15
CN104860907A (zh) 2015-08-26
WO2011156321A1 (en) 2011-12-15
US20130116317A1 (en) 2013-05-09
WO2011156321A9 (en) 2012-04-05
CN103108868B (zh) 2015-11-25
JP5855095B2 (ja) 2016-02-09
US8722731B2 (en) 2014-05-13
ZA201209237B (en) 2015-05-27
SG186229A1 (en) 2013-01-30
US20140309297A1 (en) 2014-10-16
AU2011265047B2 (en) 2014-10-23
US9149527B2 (en) 2015-10-06
JP2013528215A (ja) 2013-07-08
EP2576532B1 (en) 2018-07-18
CA2801778A1 (en) 2011-12-15
US20160024040A1 (en) 2016-01-28
EP2576532A1 (en) 2013-04-10
CA2801778C (en) 2018-06-05
MX367469B (es) 2019-08-23

Similar Documents

Publication Publication Date Title
NZ729643A (en) Combination therapy for treating cancer
SG10201907684PA (en) Androgen receptor modulator and uses thereof
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
HK1213888A1 (zh) 治療化合物和組合物以及其作為pkm2調節劑的用途
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX346147B (es) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
PH12013501600A1 (en) Novel heterocyclic derivatives
WO2014062733A3 (en) Substituted benzene compounds
PH12014500867A1 (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases
MY165624A (en) N-acylsulfonamide apoptosis promoters
NZ604018A (en) Furanyl compounds and the use thereof
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2014100351A3 (en) 8'-hydroxy-dihydroergotamine compounds and compositions
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
MX2018002932A (es) Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
UY33219A (es) Cetoenoles cíclicos para terapias
MX2015006544A (es) Sulfonamidas con sustitucion biarilo y su uso.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
HK1229709A1 (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2016 BY HENRY HUGHES IP LIMITED

Effective date: 20150901

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2017 BY CPA GLOBAL

Effective date: 20160610

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2018 BY CPA GLOBAL

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2019 BY CPA GLOBAL

Effective date: 20180426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2020 BY PATRIX IP SERVICES

Effective date: 20190606

LAPS Patent lapsed